ACRS
Aclaris Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 1
consensus rating "Buy"
ample liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ACRS
Aclaris Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases
701 Lee Road, Suite 103, Wayne, PA 19087
--
Aclaris Therapeutics, Inc., was founded in July 2012 in Delaware, USA. The company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune inflammatory diseases.
Company Financials
EPS
ACRS has released its 2025 Q1 earnings. EPS was reported at -0.12, versus the expected -0.12, meeting expectations. The chart below visualizes how ACRS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACRS has released its 2025 Q1 earnings report, with revenue of 1.46M, reflecting a YoY change of -39.32%, and net profit of -15.09M, showing a YoY change of 10.96%. The Sankey diagram below clearly presents ACRS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
